These findings may provide novel evidence for underlying the mechanisms that activate NAFLD progression and present GAS5/miR-29a-3p/NOTCH2 regulatory axis as promising therapeutic targets for NAFLD. The gene discussed is GAS5; the disease is metabolic dysfunction-associated steatotic liver disease.